These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 20307224)

  • 1. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M; Tsukuda M
    Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann C; Herrstedt J
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):137-48. PubMed ID: 20131990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
    Schwartzberg LS; Jacobs P; Matsouka P; Azevedo W; Pinto A
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):59-70. PubMed ID: 22321726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM
    Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.
    Fabi A; Malaguti P
    Expert Opin Pharmacother; 2013 Apr; 14(5):629-41. PubMed ID: 23414148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Mori-Vogt S; Blazer M
    Expert Rev Anticancer Ther; 2013 Aug; 13(8):919-36. PubMed ID: 23984894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
    Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
    Viale PH
    Clin J Oncol Nurs; 2005 Feb; 9(1):77-84. PubMed ID: 15751501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The next generation of chemotherapy-induced nausea and vomiting prevention and control: a new 5-HT3 antagonist arrives.
    Rittenberg CN
    Clin J Oncol Nurs; 2004 Jun; 8(3):307-8, 310. PubMed ID: 15208825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs for chemotherapy-induced emesis.
    Navari RM; Province PS
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):137-51. PubMed ID: 16503832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.